Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1976 Dec;26(3):505–510.

Leukocyte migration inhibitory factor (LMIF) profile in primary and secondary immunodeficiency disease.

A J Górski, B Dupont, J A Hansen, R O'Reilly, E Smithwick, R Górska, R A Good
PMCID: PMC1540992  PMID: 795576

Abstract

Lymphocytes from patients with primary and secondary immunodeficiency disease were tested for capacity to produce LMIF after mitogen and antigen stimulation as well as for ability to stimulate and respond in unidirectional MLC-LMIF assay. Different patterns of immune abnormality in vitro were detectable when Con A and Candida albicans antigen were used. In addition, significant abnormalities in LMIF responding and stimulatory capacity were demonstrated in patients with Hodgkin's disease. LMIF production after stimulation with different agents allows for a better characterization of cellular defects in immunodeficiency disease.

Full text

PDF
505

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dupont B., Good R. A. Lymphocyte transformation in vitro in patients with immunodeficiency diseases: use in diagnosis, histocompatibility testing and monitoring treatment. Birth Defects Orig Artic Ser. 1975;11(1):477–485. [PubMed] [Google Scholar]
  2. Durkin H. G., Bash J. A., Waksman B. H. Separation of T cell subpopulations capable of DNA synthesis, lymphotoxin release, and regulation of antigen and phytohemagglutinin responses on the basis of density and adherence properties. Proc Natl Acad Sci U S A. 1975 Dec;72(12):5090–5094. doi: 10.1073/pnas.72.12.5090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Graze P. R., Perlin E., Royston I. In vitro lymphocyte dysfunction in Hodgkin's disease. J Natl Cancer Inst. 1976 Feb;56(2):239–243. doi: 10.1093/jnci/56.2.239. [DOI] [PubMed] [Google Scholar]
  4. Górski A. J., Dupont B., Hansen J. A., Good R. A. Leukocyte migration inhibitory factor (LMIF) induced by concanavalin A: standardized microassay for production in vitro. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3197–3200. doi: 10.1073/pnas.72.8.3197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hansen J. A., Good R. A. Malignant disease of the lymphoid system in immunological perspective. Hum Pathol. 1974 Sep;5(5):567–599. doi: 10.1016/s0046-8177(74)80007-9. [DOI] [PubMed] [Google Scholar]
  6. Holm G., Mellstedt H., Björkholm M., Johansson B., Killander D., Sundblad R., Söderberg G. Lymphocyte abnormalities in untreated patients with Hodgkin's disease. Cancer. 1976 Feb;37(2):751–762. doi: 10.1002/1097-0142(197602)37:2<751::aid-cncr2820370223>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  7. Kasakura S. MLC stimulatory capacity and production of blastogenic factor in patients with chronic lymphatic leukemia and Hodgkin's disease. Blood. 1975 Jun;45(6):823–832. [PubMed] [Google Scholar]
  8. Rees J. C., Rossio J. L., Wilson H. E., Minton J. P., Dodd M. C. Cellular immunity in neoplasia. Antigen and mitogen responses in patients with bronchiogenic carcinoma. Cancer. 1975 Dec;36(6):2010–2015. doi: 10.1002/cncr.2820360913. [DOI] [PubMed] [Google Scholar]
  9. Rocklin R. E., MacDermott R. P., Chess L., Schlossman S. F., David J. R. Studies on mediator production by highly purified human T and B lymphocytes. J Exp Med. 1974 Nov 1;140(5):1303–1316. doi: 10.1084/jem.140.5.1303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rocklin R. E. Partial characterization of leukocyte inhibitory factor by concanavalin A-stimulated human lymphocytes (LIF Con A). J Immunol. 1975 Apr;114(4):1161–1165. [PubMed] [Google Scholar]
  11. Ruthlomnitzer, Rabson A. R., Koornhof H. J. Production of leucocyte inhibitory factor (LIF) and macrophage inhibitory factor (MIF) by PHA-stimulated lymphocytes. Clin Exp Immunol. 1975 Dec;22(3):522–527. [PMC free article] [PubMed] [Google Scholar]
  12. Simó-Camps E., Anguers A., Ma Vich J., Vidal-Ribas A., Sala F., Sarrias R., Gumma J., Gri E., Ma Puigdollers J. Immunologic impairment in patients with non-lymphoid cancer: correlation with the tumoral stage, response to treatment and survival. Cancer. 1976 Feb;37(2):724–728. doi: 10.1002/1097-0142(197602)37:2<724::aid-cncr2820370219>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  13. Stobo J. D., Paul S., Van Scoy R. E., Hermans P. E. Suppressor thymus-derived lymphocytes in fungal infection. J Clin Invest. 1976 Feb;57(2):319–328. doi: 10.1172/JCI108283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Twomey J. J., Laughter A. H., Farrow S., Douglass C. C. Hodgkin's disease. An immunodepleting and immunosuppressive disorder. J Clin Invest. 1975 Aug;56(2):467–475. doi: 10.1172/JCI108113. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES